The timing of RSV protection matters critically for newborn survival, and a new comparison reveals maternal vaccination may offer superior infant defense against severe respiratory illness. This finding could reshape how clinicians approach RSV prevention during the vulnerable first months of life.
French researchers analyzed over 50,000 matched infant pairs to compare two preventive approaches: maternal RSVpreF vaccination during weeks 32-36 of pregnancy versus direct infant immunization with nirsevimab antibodies after birth. The population-based study tracked RSV-related hospitalizations through February 2025, measuring not just admission rates but intensive care needs, ventilator requirements, and oxygen therapy demands. Maternal vaccination demonstrated measurably stronger protection against severe RSV outcomes compared to passive infant immunization.
This head-to-head comparison addresses a crucial gap in pediatric infectious disease management. RSV remains the leading cause of infant hospitalization globally, with premature and young infants facing the highest risk of severe complications. The study's strength lies in its large matched cohort design and comprehensive outcome tracking through national health records. However, the relatively short follow-up period and single-season data collection limit long-term conclusions about durability of protection. The findings suggest maternal vaccination may provide more robust early-life immunity through sustained placental antibody transfer, potentially offering longer-lasting protection than post-birth passive immunization. For healthcare systems worldwide grappling with RSV burden, these results support prioritizing maternal vaccination programs over reactive infant treatment strategies, though optimal implementation will require careful consideration of vaccination timing, coverage rates, and healthcare infrastructure capabilities.